Skip to main content
SpringerLink
Log in

Jéjuno-iléite ulcéreuse à la Clofazimine Aspects radiologiques et endoscopiques

Ulcerative jejuno-ileitis related to Clofazimine endoscopic and radiological features

  • Published:
Acta Endoscopica

Résumé

Les auteurs rapportent deux observations d’entérite ulcéreuse à la Clofazimine caractérisée par des lésions érosives à prédominance iléale.

La Clofazimine — dérivé du tartrate de phendimetrazine — utilisée dans le traitement de la lèpre, du pyoderma gangrenosum et du lupus erythémateux chronique, provoque des lésions œdémateuses et ulcéreuses aphtoïdes du grêle, lentement régressives après arrêt du médicament.

Le diagnostic des lésions reste radiologique, mais l’entéroscopie dans un cas a permis leur mise en évidence au niveau jéjunal. L’histologie n’est pas spécifique. Des lésions d’entérite à eosinophiles et des dépôts de cristaux de Clofazimine dans les ganglions mésentériques et la paroi intestinale ont été mis en évidence lors d’autopsies de sujets décédés de la lèpre.

Summary

The authors report two cases of ulcerative enteritis related to clofazimine characterised by erosive lesions predominantly in the ileum.

Clofazimine, a derivative of phendimetrazine tartrate used in the treatment of leprosy, pyoderma gangrenosum and chronic lupus erythematosus, causes oedematous, ulcerative, aphtoid lesions of the small intestine which slowly regress once the medication is stopped.

The diagnosis of the lesions is primarily radiological, although, in one case, enteroscopy was able to reveal such lesions in the jejunum. The histology is nonspecific. Autopsies of subjects who died from leprosy revealed eosinophilic enteritis lesions and Clofazimine crystal deposits in the mesenteric lymph nodes and in the walls of the intestine.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Bibliographie

  1. ATKINSON A.J., SHEAGREN J.N., RUBIO J.B., KNIGHT V. — Evaluation of B 663 in human leprosy.Int. J. Lep., 1967,35, 119–127.

    Google Scholar 

  2. BALAKRISHNAN S., DESIKAN K.V. and RAMU G. — Quantitative estimation of Clofazimine in tissues.Leprosy in India, 1976,48, 732–738.

    PubMed  CAS  Google Scholar 

  3. BARRY V.C., BELTON J.G., CONALTY M.L., DENOONY J.M., EDWARD D.W., O’SULLIVAN J.F., TWONEY D., WINDER F. — A few series of phenazine (rimino-compounds) with high antituberculosis activity.Nature (Lond.), 1957,179, 1013–1015.

    Article  CAS  Google Scholar 

  4. BARRY V.C., CONALTY M.L. — Antituberculosis activity in the phenazine series II.N3-substituted anilino-aposafranines (rimino-compounds) and some derivatives.Am. Rev. Tuberc. Pulm. Dis., 1958,78, 62–73.

    CAS  Google Scholar 

  5. BEUREY J., WEBER M., DELROUS J.L., CHAULIEU Y. — Pyoderma gangrenosum: thérapeutique par Clofazimine.Ann. Derm. Venereol., 1977,104, 631–634.

    PubMed  CAS  Google Scholar 

  6. BRANDT L. — Phagocytosis-promoting effect of Clofazimine (B 663) in patients with subnormal granulocyte function.Scan. J. Haemat., 1971,8, 400–404.

    CAS  Google Scholar 

  7. BRANDT L., GARTNER I., NILSSON P.G., OLOFSSON T. — Pyoderma gangrenosum associated with regional enteritis.Acta Med. Scand., 1977,201, 141–144.

    PubMed  CAS  Google Scholar 

  8. BROWNE S.G., HOGERZEIL L.M. — B 663 in the treatment of leprosy. Preliminary report of a pilot trial.Lepr. Rev., 1962,33, 6–10.

    PubMed  CAS  Google Scholar 

  9. CLAUDY A.L., GOGUE Y., VOLLE H. — Pyoderma gangrenosum associé à une polyarthrite séro-négative.Ann. Derm. Venereol., 1978,105, 701–704.

    PubMed  CAS  Google Scholar 

  10. CONALTY M.L., JACKSON R.D. — Uptake by reticulo-endothelial cells of the rimino-phenazine B 663 (2 P-Chloroanilino-5 P-Chlorophenyl-3: 5-dihydro-3 isopropylinino-phenazine).Brit. J. Exp. Path., 1962,6, 650–654.

    Google Scholar 

  11. CONALTY M.L., BARRY V.S., JINA A. — The antileprosy agent B 663 (Clofazimine) and the reticulo-endotheliel system.International Journal of Leprosy, 1971,39, 479–492.

    CAS  Google Scholar 

  12. DE BERGEYCK E., JANSSENS P.G., DE MUYNDK A. — Ileitis granulomatosa: radiologische diagnose na langdurige toediening van Clofazimine.Ned. T. Geneesk., 1979, 123–146.

  13. DESIKAN K.V., RAMANUJAM K., RAMU G., BALAKRISHNAN S. — Autopsy findings in a case of lepromatous leprosy treated by Clofazimine.Lep. Rev., 1975,46, 181–189.

    CAS  Google Scholar 

  14. DESIKAN K.V., BALAKRISHNAN S. — Tissue levels of Clofazimine in a case of leprosy.Lepr., Rev., 1976,47, 107–113.

    CAS  Google Scholar 

  15. DUPRE A., BONAFE J.L., LASSERE J., ALBRAREL N., CHRISTOL B. — Traitement du lupus érythémateux chronique par le lamprène (Clofazimine). Etude préliminaire.Ann. Dermatol. Vénéréol., 1978,105, 423–425.

    PubMed  CAS  Google Scholar 

  16. HASTINGS R.C., JACOBSON R.R., TRAUTMAN J.R. — Long-terne Clinical Toxicity studies with Clofazimine (B 663) in leprosy.Internat. J. of Leprosy, 1976,44, 287–293.

    CAS  Google Scholar 

  17. KRIVANEK J., PAVER W.K., KOSSARD S., CAINS G. — Clofazimine (lamprène) in the treatment of discoid lupus erythematosus.Aust. J. Derm., 1976,17, 108–110.

    Article  CAS  Google Scholar 

  18. JOPLING W.H. — Complications of treatment with Clofazimine (lamprène B 663).Lepr. Rev., 1976,47, 1.

    PubMed  CAS  Google Scholar 

  19. MACKEY J.P., BARNES J. — Clofazimine in the treatment of discoid lupus erythematous.Brit. J. Dermat., 1974,91, 93–96.

    Article  CAS  Google Scholar 

  20. MASON G.H., ELLIS-PEGLER R.B., ARTHUR J.F. — Clofazimine and eosinophilic enteritis.Lepr. Rev., 1977,48, 175–180.

    PubMed  CAS  Google Scholar 

  21. MICHAELSSON G., MOLIN L., OHMAN S., LINDSTROM B., SKOGH M., TROLIN I. — Clofazimine: a new agent for the treatment of pyoderma gangrenosum.Arch. Dermatol., 1976,112, 344–349.

    Article  PubMed  CAS  Google Scholar 

  22. RAMU G., IYER C.G.S. — Side effects of Clofazimine therapy.Leprosy in India, 1976,48, 722–731.

    PubMed  CAS  Google Scholar 

  23. ROSTANT M. — Le lamprene en léprologie.Act. Leprol., 1972,46–47, 93–103.

    Google Scholar 

  24. SABET T., NEWLIN C., FRIEDMAN H. — Effects of RES blokade on antibody formation. I. Suppressed cellular and humoral haemolysin responses in mice injected with carbon particles.Immunology, 1969,16, 433.

    PubMed  CAS  Google Scholar 

  25. SHEAGREN J.N. — Antimalarial effect of B 663 in mice infected with plasmodium berghei.J. of. Parasitology, 1968,54, 1250.

    Article  CAS  Google Scholar 

  26. YAWALKAR S.J., VISCHER W. — Lamprene (Clofamizine) in leprosy.Lepr. Rev., 1979,30, 135–144.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cliniques Universitaires St-Luc U.C.L., Louvain-en-W. 10, avenue Hippocrate, 1200, Bruxelles, Belgique

    P. Mainguet, A. Bourlond, A. Saussez de Temmerman, J. Pringot & J. Haot

Authors
  1. P. Mainguet
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Bourlond
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Saussez de Temmerman
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. Pringot
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J. Haot
    View author publications

    You can also search for this author in PubMed Google Scholar

About this article

Cite this article

Mainguet, P., Bourlond, A., Saussez de Temmerman, A. et al. Jéjuno-iléite ulcéreuse à la Clofazimine Aspects radiologiques et endoscopiques. Acta Endosc 10, 307–316 (1980). https://doi.org/10.1007/BF02978274

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02978274

Mots-clés

Key-words

Search

Navigation